2009: Immunotec announces important clinical research initiative: New study to be launched with the goal of improving the quality of the agi...( Immunotec Receives NHPD/Health Cana...)

    Immunotec Receives NHPD/Health Canada Authorization to Begin a Study on
    the Effect of the Cysteine-Rich Whey Protein Isolate (Immunocal(R)) in
    Combination with Physical Exercise on Muscle Function, Body Composition
    and Inflammatory Cytokine Levels in Elderly Persons: A Randomized,
    Double-Blind Study.

MONTREAL, July 7 /PRNewswire-FirstCall/ - Immunotec Inc. (TSX-V: IMM) announced today that the Natural Health Products Directorate (NHPD) - a division of Health Canada responsible for evaluating the safety, efficacy and quality of natural health products (NHPs) - granted authorization for Immunotec to conduct a clinical trial of IMMUNOCAL(R) in elderly persons.

Aging is typically associated with a decrease in skeletal muscle mass and muscle function, which contributes decisively to disability in old age and to a loss of quality of life. Resistance training exercise can increase muscle strength, function and mass in older adults.

The primary aim of this study is to determine whether taking a cysteine-rich whey protein isolate (IMMUNOCAL(R)) compared to casein (a milk protein used as control, which contains little cysteine) may optimize the quality of life in the elderly. The consumption of these proteins will be evaluated in association with resistance training to determine if the combination of Immunocal(R) with exercise will provide significant gains in muscle strength, muscle mass and cognitive functions, compared to the same training program combined with taking casein, the control protein. Benefits in these fields can be translated to improved quality of life for elderly persons.

The Principal Investigator, Dr. Remi Rabasa-Lhoret, MD, PhD, Associate Research Professor and Metabolic Unit Laboratory Director, Institut de recherches cliniques de Montreal (IRCM) and his research team are very enthusiastic about the prospects of the trial. "Immunotec should be commended for initiating and sup
'/>"/>